[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,098,798
  • Shares Outstanding, K 43,883
  • Annual Sales, $ 451,360 K
  • Annual Income, $ -66,420 K
  • EBIT $ -49 M
  • EBITDA $ -52 M
  • 60-Month Beta 0.53
  • Price/Sales 6.73
  • Price/Cash Flow N/A
  • Price/Book 8.72

Options Overview Details

View History
  • Implied Volatility 47.72% (+3.70%)
  • Historical Volatility 53.92%
  • IV Percentile 11%
  • IV Rank 22.08%
  • IV High 82.12% on 04/17/26
  • IV Low 37.97% on 08/20/25
  • Expected Move (DTE 3) 1.45 (2.04%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 1.48
  • Today's Open Interest 18,246
  • Open Int (30-Day) 16,736
  • Expected Range 69.39 to 72.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.18
  • Number of Estimates 5
  • High Estimate $-0.21
  • Low Estimate $-2.23
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) -293.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.24 +28.22%
on 07/21/26
71.45 -0.87%
on 08/18/26
+10.98 (+18.35%)
since 07/17/26
3-Month
53.89 +31.43%
on 07/15/26
72.50 -2.30%
on 07/07/26
+8.01 (+12.75%)
since 05/18/26
52-Week
48.20 +46.95%
on 09/15/25
85.25 -16.91%
on 12/09/25
+16.22 (+29.70%)
since 08/18/25

Most Recent Stories

More News
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705...

TARS : 70.07 (-0.76%)
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified...

TARS : 70.07 (-0.76%)
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the...

TARS : 70.07 (-0.76%)
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026...

TARS : 70.07 (-0.76%)
Tarsus's Demodex Franchise Faces Its First Post-Launch Profitability Test

Barchart Research What to Expect from TARS Earnings TARS Generated August 4, 2026 Current Price $61.11 EPS Estimate $$-0.21 Consensus Rating Strong Buy Average Move 6.47% Tarsus's Demodex Franchise Faces...

TARS : 70.07 (-0.76%)
5 Best ETFs for the Rest of 2026

We look at five ETFs that can help investors leverage some of the trends expected to define the markets in the back half of the year.

CTVA : 77.78 (+2.33%)
JNJ : 269.12 (+2.57%)
TARS : 70.07 (-0.76%)
ABBV : 254.76 (+1.77%)
BOTZ : 36.83 (-2.62%)
MUFG : 22.82 (-0.91%)
HSBC : 103.92 (+0.12%)
NSRGY : 97.4100 (+0.68%)
XLB : 52.11 (-0.25%)
ASML : 1,803.41 (-4.23%)
LIN : 481.59 (+1.53%)
COLL : 28.52 (+1.60%)
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity...

TARS : 70.07 (-0.76%)
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide...

TARS : 70.07 (-0.76%)
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (“Achieve” or the “Company”) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company...

MANE : 108.67 (+0.42%)
TARS : 70.07 (-0.76%)
ACHV : 7.44 (-0.80%)
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: ...

TARS : 70.07 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 73.43
2nd Resistance Point 72.10
1st Resistance Point 71.36
Last Price 70.07
1st Support Level 69.29
2nd Support Level 67.96
3rd Support Level 67.22

See More

52-Week High 85.25
Fibonacci 61.8% 71.10
Last Price 70.07
Fibonacci 50% 66.72
Fibonacci 38.2% 62.35
52-Week Low 48.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.